The development of new anticoagulant drugs opened several options in the management of venous thrombo-embolism.
The efficacy and safety of these new oral anticoagulants in specific population as elderly and those with renal impairment deserve future research.
At that time, only rivaroxaban is licensed in France, in the treatment of deep venous thrombosis.